MYND Life Sciences Expands Intellectual Portfolio to Target Alzheimer’s disease and related forms of Dementia with Chemical Subclasses of Psilocybin Analogues
You won’t want to forget about this company when choosing your investments. The research team at MYND Life Sciences Inc. (MYND) has been exploring new subclasses of psilocybin that have shown potential to delay or reverse Alzheimer’s disease and other forms of dementia. The preclinical research has shown significant progress, and MYND aims to commence clinical trials to advance the research.